Vincent Brichard

Biography

 Mr. Vincent Brichard, MD, Ph.D., MBA, is a Venture Partner at Life Sciences Partners BV since joining in 2015. He served as a Strategic Advisor at Celyad SA from September 14, 2015 to November 21, 2015. Mr. Brichard served as Vice President of Immuno-Oncology at Celyad SA from January 2015 to September 14, 2015. Mr. Brichard leads the newly acquired immuno-oncology technology platform of Cardio3 BioSciences. He started his academic career at the Ludwig Institute for Cancer Research, Brussels Branch, followed by positions at the Institut Curie Cancer Center, Paris, and at the University of Louvain, Brussels. In 2002, he joined GlaxoSmithKline Biologicals, where he led the Cancer Vaccines Business Unit. Until recently, he was the Senior Vice President of the Immunotherapeutics Business Unit, and member of the Vaccines Executive team at GSK Biologicals. He headed the Business Unit for Immunotherapeutics. He had the position of a Professor of Oncology at Louvain University. He is member of scientific advisory boards and supervisory boards of several European life sciences companies active in the fields of immuno-oncology, vaccines and diagnostics. He served as an Independent Member of Supervisory Board of Kiadis Pharma N.V. since May 2015 until April 16, 2016. Mr. Brichard has more than 25 years’ experience in the oncology and immunology field. He authored more than a 100 research manuscripts in leading international journals. He studied medicine at the Louvain University in Brussels and Institute Curie in Paris, received his Ph.D. in tumor immunology at the Ludwig Institute for Cancer Research in Brussels. He is a physician by training, specialized in oncology, and holds a PhD in tumor immunology. He also holds an MBA from the Harvard Business School.

Research Interest

Immuno-oncology technology